Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fesoterodine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.90 |
| ▸ | CHRM3 known ✓ | P20309 | 10/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fesoterodine SCHEMBL31043343 | 1.00 | CHRM2 (0.90) | CHRM2CHRM1KDM4EPOLBCHRM3 | |
| Fesoterodine SCHEMBL1993632 | 1.00 | CHRM2 (0.90) | CHRM2CHRM1KDM4EPOLBCHRM3 | |
| Fesoterodine SCHEMBL1993629 | 1.00 | CHRM2 (0.90) | CHRM2CHRM1KDM4EPOLBCHRM3 | |
| Fesoterodine SCHEMBL29366015 | 0.95 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fesoterodine SCHEMBL121127 | 0.95 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fesoterodine SCHEMBL15148766 | 0.95 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fesoterodine SCHEMBL1808421 | 0.95 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fesoterodine SCHEMBL812986 | 0.95 | CHRM2 (1.00) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fesoterodine SCHEMBL3688110 | 0.94 | CHRM2 (0.98) | CHRM2CHRM1CHRM3CHRM5HRH1 | |
| Fesoterodine SCHEMBL2474276 | 0.94 | CHRM2 (0.98) | CHRM2CHRM1CHRM3CHRM5HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| US-20240165134-A1 | COMPOSITIONS AND METHODS FOR TREATING BLADDER CONDITIONS | HADASIT MEDICAL RES SERVICES & DEVELOPMENT COMPANY LTD (IL) | 2024-05-23 | — | — | US | claimed |
| EP-4277618-A1 | COMPOSITIONS AND METHODS FOR TREATING BLADDER CONDITIONS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT COMPANY, LTD. (IL) | 2023-11-22 | — | — | EP | claimed |
| WO-2022153261-A1 | COMPOSITIONS AND METHODS FOR TREATING BLADDER CONDITIONS | HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT COMPANY LTD. (IL) | 2022-07-21 | — | — | WO | claimed |
| US-20260027111-A1 | METHODS OF TREATMENT | Bow River LLC (US) | 2026-01-29 | — | — | US | disclosed |
| EP-3731931-B1 | MODIFIED RELEASE FORMULATIONS OF FESOTERODINE | SANOVEL ILAC SANAYI VE TICARET AS (TR) | 2025-11-26 | — | — | EP | disclosed |
| US-20250332232-A1 | TRANSMUCOSAL BOTULINUM TOXIN COMPOSITIONS, KITS, AND METHODS FOR TREATING BLADDER DISORDERS | REVANCE THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12453730-B2 | Methods of treatment | Bow River LLC (US) | 2025-10-28 | — | — | US | disclosed |
| EP-4628016-A2 | DEVICES, SYSTEMS, AND METHODS FOR TRAINING PELVIC FLOOR MUSCLES | Axena Health, Inc. (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20250275924-A1 | Anticholinergic Agents and Muscarinic Agonists for the Treatment of Demodex Related Conditions | ATTILLAPS HOLDINGS INC. | 2025-09-04 | — | — | US | disclosed |
| EP-4605082-A1 | BETA-ADRENERGIC AGONIST AND MUSCARINIC ANTAGONIST COMPOSITIONS AND METHODS OF USING | Bonafide Health, LLC (US) | 2025-08-27 | — | — | EP | disclosed |
| US-20250222010-A1 | COMPOSITIONS OF BILE ACIDS AND PHENYLBUTYRATE COMPOUNDS | AMYLYX PHARMACEUTICALS, INC. | 2025-07-10 | — | — | US | disclosed |
| EP-2029567-B1 | PROCESS FOR THE PRODUCTION OF BENZOPYRAN-2-OL DERIVATIVES | PFIZER LTD (GB) | 2010-09-08 | — | — | EP | disclosed |
| US-7670621-B2 | Transdermal administration of (R)-3,3-diphenylpropylamin-monoesters | SCHWARZ PHARMA AG (DE) | 2010-03-02 | — | — | US | disclosed |
| WO-2010018484-A1 | NEW USES OF DIISOPROPYLAMINE DERIVATIVES | PFIZER LIMITED (GB) | 2010-02-18 | — | — | WO | disclosed |
| US-20090306384-A1 | Process for the Production of Benzopyran-2-ol Derivatives | PFIZER INC | 2009-12-10 | — | — | US | disclosed |
| US-20090274761-A1 | TRANSDERMAL DELIVERY OF (R)-3,3-DIPHENYLPROPYLAMIN-MONOESTERN | SCHWARZ PHARMA AG (DE) | 2009-11-05 | — | — | US | disclosed |
| US-20090012159-A1 | HIGH PURITY BASES OF 3,3-DIPHENYLPROPYLAMINO MONOESTERS | UCB PHARMA GMBH (DE) | 2009-01-08 | — | — | US | disclosed |
| US-20060029673-A1 | Transdermal administration of (r)-3,3-diphenylpropylamin-monoesters | SCHWARZ PHARMA AG (DE) | 2006-02-09 | — | — | US | disclosed |
| US-20060014832-A1 | Highly pure bases of 3,3-dipheyl propylamine monoesters | SCHWARZ PHARMA AG (DE) | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014832-A1 | Highly pure bases of 3,3-dipheyl propylamine monoesters | ADRB3, DRD3, CYP3A5 | CHRM2 210/4885CHRM3 73/4885CHRM1 189/4885 |
| US-20090012159-A1 | HIGH PURITY BASES OF 3,3-DIPHENYLPROPYLAMINO MONOESTERS | CYP11B2, CYP11B1, CYP21A2 | CHRM2 913/4885CHRM3 555/4885CHRM1 780/4885 |
| US-20260027111-A1 | METHODS OF TREATMENT | BRCA1, CYP2C19, CYP19A1 | CHRM2 2379/4885CHRM3 2893/4885CHRM1 3344/4885 |
| US-20250222010-A1 | COMPOSITIONS OF BILE ACIDS AND PHENYLBUTYRATE COMPOUNDS | SLC10A2, SLC10A1, GPBAR1 | CHRM2 4448/4885CHRM3 2831/4885CHRM1 4740/4885 |
| US-20090274761-A1 | TRANSDERMAL DELIVERY OF (R)-3,3-DIPHENYLPROPYLAMIN-MONOESTERN | PLOD3, TH, CYP1A1 | CHRM2 333/4885CHRM3 70/4885CHRM1 169/4885 |
| US-20060029673-A1 | Transdermal administration of (r)-3,3-diphenylpropylamin-monoesters | CYP2D6, CYP2C9, CYP2F1 | CHRM2 392/4885CHRM3 95/4885CHRM1 171/4885 |
| US-20090306384-A1 | Process for the Production of Benzopyran-2-ol Derivatives | ADRB2, TACR2, TACR1 | CHRM2 32/4885CHRM3 56/4885CHRM1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.